Hypothesis driven development of new adjuvants: Short peptides as immunomodulators

Jessica C. Dong, Gary P. Kobinger

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


To date, vaccinations have been one of the key strategies in the prevention and protection against infectious pathogens. Traditional vaccines have well-known limitations such as safety and efficacy issues, which consequently deems it inappropriate for particular populations and may not be an effective strategy against all pathogens. This evidence highlights the need to develop more efficacious vaccination regiments. Higher levels of protection can be achieved by the addition of immunostimulating adjuvants. Many adjuvants elicit strong, undefined inflammation, which produces increased immunogenicity but may also lead to undesirable effects. Hypothesis driven development of adjuvants is needed to achieve a more specific and directed immune response required for optimal and safe vaccineinduced immune protection. An example of such hypothesis driven development includes the use of short immunomodulating peptides as adjuvants. These peptides have the ability to influence the immune response and can be extrapolated for adjuvant use, but requires further investigation.

Original languageEnglish (US)
Pages (from-to)808-811
Number of pages4
JournalHuman Vaccines and Immunotherapeutics
Issue number4
StatePublished - Apr 2013
Externally publishedYes


  • Adjuvant development
  • Immunomodulating peptides
  • Novel adjuvants
  • Peptide adjuvants
  • Vaccine development

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Hypothesis driven development of new adjuvants: Short peptides as immunomodulators'. Together they form a unique fingerprint.

Cite this